Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.
Dr. John Cush RheumNow
11 months 2 weeks ago
ChildCAPTURE & BioCAPTURE registry studies of 117 pediatric & 243 young adult Psoriasis pts on biologics (753.4 Pt-Yrs) shows no sex differences in clinical responses, but shows females have more adverse events than males (both cohorts) https://t.co/5at9vCqwIO https://t.co/ScJkIH9G31
Sjögren syndrome is now Sjögren disease, according to recommendations stemming from the 2023 International Rome consensus for the nomenclature of Sjögren disease.
Dr. John Cush RheumNow
11 months 2 weeks ago
Uncertainty with immunosuppressive for idiopathic inflammatory myopathies
A current Cochrane review suggests a continued unmet need regarding the status and utility of targeted immunosuppressant and immunomodulatory treatments for IIM.
https://t.co/evkwbX6U9j https://t.co/2s0Z9Y9Umm
Dr. John Cush RheumNow
11 months 2 weeks ago
Claims data study of 82 399 PsA pts - 542 on combo targeted Rx >3 mos (200 > 6mos). 2 most common combos of apremilast w/ TNFi or IL-17i. Use of combo targeted Tx was not assoc. w/ more serious infxn (RRs 0.53; 0.17-1.63) or opportunistic infx (RR 1.00; 0.09-11.02) @ 3 or 6 mos https://t.co/mkvq1lqt9Y
Dr. John Cush RheumNow
11 months 2 weeks ago
RCT of 2331 chronic MSK pain pts showed that telehealth Cognitive behavioral therapy (CBT) (health coach) superior to self-care (Pain trainer) or usual care at achieving a >30% reduction in pain (32% vs 26.6% vs 20.8% respectively) & benefits were sustained at 12 months. https://t.co/a69zPsJslH
A long-term cohort study of children diagnosed with Kawasaki disease (KD) shows evidence of future adult cardiovascular complications and hospitalizations. These severe cardiovascular events clustered during the young KD adults and later, a second surge in their late 30s.
Dr. John Cush RheumNow
11 months 2 weeks ago
The global autoimmune disease treatment market was valued at $7 billion USD in 2024 and is expected to rise to ~$11 billion by 2030 and reach $12.6 billion by 2032 https://t.co/C5IQ0hUvQE https://t.co/RjbMo5cCOl
Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased risk of serious infections, insurance claims data indicate.
Aravind Palraj Rheumat_Aravind
11 months 2 weeks ago
Clinical Rheumatology Thread for Busy GPs:
Post 1
Early inflammatory arthritis(IA): the 3–3–3 rule
•Onset ≤3 months
•Morning stiffness ≥30–60 minutes
•≥3 swollen joints (MCP/MTP common)
If present, manage as IA: urgent rheum referral; NSAIDs if no contraindications. https://t.co/hcoumX1ZVY
The third survey in this series addressed clinician views on future trends (AI), future therapies and lessons learned.This survey captured 233 responses from rheumatologists (91), most (61%) from the USA. US respondents were from the Southeast (17.5%), Southwest (11.4%), Mid-Atlantic (9.6%) or Western (9.6%) states.
Dr. John Cush RheumNow
11 months 2 weeks ago
TNF Inhibitors in Takayasu's Arteritis
A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis.
https://t.co/lJbvaYnylO https://t.co/uRBruhW2Fd
sergio serrano belmar sserranobmsk
11 months 2 weeks ago
Tarsal Tunnel Syndrome: An Ultrasound Pictorial Review
https://t.co/Qr4ehZo41p
Tarsal tunnel syndrome (TTS) is an entrapment neuropathy caused by compression of the posterior tibial nerve or its branches as they pass beneath the flexor retinaculum at the medial ankle. Clinical https://t.co/FivPCl7EvU
Dr. John Cush RheumNow
11 months 2 weeks ago
Guidance on aromatase inhibitor-associated bone loss with hormone-sensitive breast cancer
An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for https://t.co/ZkvToBBGdB
Dr. John Cush RheumNow
11 months 2 weeks ago
Detailed comprehensive overview of GLP-1RAs and SGLT2 inhibitors - their benefits w/ inflammatory conditions, & potential antiinflammatory effects. Bi-directional interplay between obesity, inflammation, and comorbid diseases https://t.co/oAQsuWVbZO https://t.co/SNqngATBtv
